- Home
- CDNA vs AUPH Comparison
CDNA vs AUPH Comparison
Compare CDNA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- AUPH
- Stock Information
- Founded
- CDNA 1998
- AUPH 1993
- Country
- CDNA United States
- AUPH Canada
- Employees
- CDNA N/A
- AUPH N/A
- Industry
- CDNA Medical Specialities
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CDNA Health Care
- AUPH Health Care
- Exchange
- CDNA Nasdaq
- AUPH Nasdaq
- Market Cap
- CDNA 1.0B
- AUPH 1.1B
- IPO Year
- CDNA 2014
- AUPH 1999
- Fundamental
- Price
- CDNA $19.04
- AUPH $7.77
- Analyst Decision
- CDNA Buy
- AUPH Strong Buy
- Analyst Count
- CDNA 6
- AUPH 2
- Target Price
- CDNA $30.33
- AUPH $11.50
- AVG Volume (30 Days)
- CDNA 996.2K
- AUPH 1.1M
- Earning Date
- CDNA 07-30-2025
- AUPH 07-31-2025
- Dividend Yield
- CDNA N/A
- AUPH N/A
- EPS Growth
- CDNA N/A
- AUPH N/A
- EPS
- CDNA 1.07
- AUPH 0.27
- Revenue
- CDNA $346,421,000.00
- AUPH $247,295,000.00
- Revenue This Year
- CDNA $13.31
- AUPH $12.15
- Revenue Next Year
- CDNA $15.46
- AUPH $18.31
- P/E Ratio
- CDNA $17.61
- AUPH $29.24
- Revenue Growth
- CDNA 25.92
- AUPH 29.20
- 52 Week Low
- CDNA $13.48
- AUPH $5.20
- 52 Week High
- CDNA $34.84
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CDNA 55.64
- AUPH 38.94
- Support Level
- CDNA $18.51
- AUPH $8.08
- Resistance Level
- CDNA $19.62
- AUPH $8.29
- Average True Range (ATR)
- CDNA 0.84
- AUPH 0.19
- MACD
- CDNA 0.02
- AUPH -0.03
- Stochastic Oscillator
- CDNA 66.12
- AUPH 5.00
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.